Pasithea Therapeutics Corporation (KTTA) Actualités

Pasithea Therapeutics to Participate in H.C. Wainwright 25th Annual Global Investment Conference

-- Attendees may request 1 x 1 meeting with management at meetings@hcwco.com --  PALO ALTO, Calif. and MIAMI...

Form SC TO-I/A - Tender offer statement by Issuer: [Amend]

Form SC TO-I/A - Tender offer statement by Issuer: [Amend]

Form SC TO-I/A - Tender offer statement by Issuer: [Amend]

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form SC TO-I - Tender offer statement by Issuer

Pasithea Therapeutics publishes study in Proceedings of the National Academy of Sciences (PNAS) that shows an increase in α5 integrin expression in ALS human and mouse brain tissue, and further demonstrates targeting α5 integrin results in improved survi

-- PAS-003 is a monoclonal antibody targeting α5/β1 integrin for the treatment of amyotrophic lateral sclerosis...

Form SC TO-C - Written communication relating to an issuer or third party

Form 8-K - Current report

Pasithea Therapeutics Announces Intention to Commence a $4.0 Million Tender Offer for its Common Stock at Price of $0.70 per Share in Cash

PALO ALTO, Calif. and MIAMI, July 20, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA...

Pasithea Therapeutics Special Committee Rejects Unsolicited Bid from Lucy Scientific Discovery, Inc.

PALO ALTO, Calif. and MIAMI, July 20, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA...

Form 8-K - Current report

Form 3 - Initial statement of beneficial ownership of securities

Pasithea Therapeutics Confirms Previous Creation of Independent Special Committee of its Board of Directors

PALO ALTO, Calif. and MIAMI, June 30, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA...

Lucy Scientific Discovery Reiterates Its Proposal to Acquire Pasithea Therapeutics Corp.

VANCOUVER, British Columbia, June 29, 2023 (GLOBE NEWSWIRE) -- Lucy Scientific Discovery Inc. (“Lucy” or “the...